Cowen Inc. bought a new stake in shares of NxStage Medical, Inc. (NASDAQ:NXTM) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 69,100 shares of the medical device company’s stock, valued at approximately $1,908,000. Cowen Inc. owned approximately 0.10% of NxStage Medical at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Birchview Capital LP grew its stake in shares of NxStage Medical by 21.3% in the 2nd quarter. Birchview Capital LP now owns 34,200 shares of the medical device company’s stock valued at $857,000 after buying an additional 6,000 shares in the last quarter. Gabelli Funds LLC bought a new stake in shares of NxStage Medical in the 3rd quarter valued at approximately $4,941,000. Redmile Group LLC bought a new stake in shares of NxStage Medical in the 2nd quarter valued at approximately $16,480,000. ARP Americas LLC bought a new stake in shares of NxStage Medical in the 3rd quarter valued at approximately $11,219,000. Finally, Delta Lloyd Asset Management N.V. bought a new stake in shares of NxStage Medical in the 2nd quarter valued at approximately $4,638,000. 85.68% of the stock is owned by institutional investors and hedge funds.

In other news, SVP Winifred L. Swan sold 3,500 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $25.73, for a total transaction of $90,055.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Matthew W. Towse sold 4,300 shares of the company’s stock in a transaction that occurred on Wednesday, September 20th. The stock was sold at an average price of $27.27, for a total value of $117,261.00. Following the transaction, the senior vice president now owns 28,721 shares of the company’s stock, valued at $783,221.67. The disclosure for this sale can be found here. Insiders have sold 12,300 shares of company stock valued at $331,126 in the last ninety days. Company insiders own 4.70% of the company’s stock.

NXTM has been the subject of several recent research reports. Canaccord Genuity reissued a “hold” rating and issued a $30.00 price target on shares of NxStage Medical in a research note on Tuesday, October 17th. Zacks Investment Research cut NxStage Medical from a “hold” rating to a “sell” rating in a research report on Tuesday, November 14th. Northland Securities reaffirmed a “hold” rating and set a $30.00 target price on shares of NxStage Medical in a research report on Wednesday, November 8th. Leerink Swann cut NxStage Medical from an “outperform” rating to a “market perform” rating and upped their target price for the stock from $28.00 to $30.00 in a research report on Tuesday, August 22nd. Finally, BTIG Research cut NxStage Medical from a “buy” rating to a “neutral” rating in a research report on Friday, August 11th. Two investment analysts have rated the stock with a sell rating and eight have given a hold rating to the company. NxStage Medical currently has a consensus rating of “Hold” and a consensus price target of $30.25.

Shares of NxStage Medical, Inc. (NASDAQ NXTM) opened at $25.60 on Friday. NxStage Medical, Inc. has a 12-month low of $20.45 and a 12-month high of $30.80.

ILLEGAL ACTIVITY WARNING: “Cowen Inc. Buys New Position in NxStage Medical, Inc. (NXTM)” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/12/08/cowen-inc-buys-new-position-in-nxstage-medical-inc-nxtm.html.

NxStage Medical Profile

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Want to see what other hedge funds are holding NXTM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NxStage Medical, Inc. (NASDAQ:NXTM).

Institutional Ownership by Quarter for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.